Flex Announces Date for Third Quarter Fiscal 2024 Earnings Call
AUSTIN, Texas, Jan. 8, 2024 /PRNewswire/ -- Flex (NASDAQ: FLEX) will announce its third quarter fiscal 2024 financial results after the market closes on Wednesday, January 31, 2024. The company will hold a conference call to discuss the results on the same day at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time).
The live webcast presentation will be available on the Flex Investor Relations (IR) website located at investors.flex.com. The webcast replay, along with supporting materials, will be available on the IR website following the conclusion of the event.
About Flex Ltd. Flex (Reg. No. 199002645H) is the manufacturing partner of choice that helps a diverse customer base design and build products that improve the world. Through the collective strength of a global workforce across 30 countries and responsible, sustainable operations, Flex delivers technology innovation, supply chain, and manufacturing solutions to diverse industries and end markets.
GIGABYTE Technology, a leading IT innovator, is at the forefront of advancing global industries through cloud and AI computing systems, enhancing user experiences through hardware innovation. At COMPUTEX 2024, GIGABYTE unveils groundbreaking products...
Highlights
Payment Fraud is top financial crime concern for 32% of Malaysians
Identity theft worries persist, with 37% believing they have or might have been victims
Real-time payment scams are on the rise, with 76% receiving scam...
Volvo Autonomous Solutions (V.A.S.) today unveiled Volvo's first-ever production ready autonomous truck at the ACT Expo in Las Vegas. The Volvo VNL Autonomous brings together Volvo's commercial vehicle expertise with industry-leading autonomous...
Casio Computer Co., Ltd. announced today the release of five new "Sky and Sea" models spanning five of its watch brands ? Casiotron, G-SHOCK, EDIFICE, PRO TREK, and BABY-G ? to commemorate the 50th anniversary of Casio watches. The design theme...
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune, ophthalmology and other major...
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. and Alvotech , today announced the availability of SIMLANDI (adalimumab-ryvk) injection in the U.S., as an interchangeable biosimilar to Humira for the treatment of adult...
